Six Significant Compounds For The CT99021

The vascular access was obtained by a double-lumen catheter (��8 Fr) placed in a major venous vessel. The following anticoagulation protocol was used: a loading bolus of 3,000�C5,000 IU heparin (2,000 UI for patients with an international normalized ratio value of 2�C4) was administered inside the circuit before allowing blood to pass into the filter; and then a continuous heparin infusion rate of 500 IU/h was maintained during the ultrafiltration session. The session duration and the ultrafiltration rate PDGFRB (100�C500 mL/h) were left to the discretion of the treating physician; the ultrafiltration rate could be changed during the procedure according to the clinical situation. Notably, the hematocrit was automatically and continuously monitored inside the extracorporeal circuit by a dedicated integrated sensor to guide ultrafiltration rate adjustments and thus prevent hypovolemia during ultrafiltration.14 The primary end point of the CUORE trial was the incidence of rehospitalizations for congestive HF in patients treated with ultrafiltration versus standard therapy. Secondary end points included: 1) all cause mortality; 2) a combined end point of death and rehospitalizations for congestive HF; 3) changes in diuretic dose, renal function, and BNP values during the follow-up. For the calculation of the sample size, we assumed a 3-month rehospitalization rate of 40% CT99021 ic50 in control subjects.21 Moreover, we assumed an incidence of rehospitalizations in the ultrafiltration group of 8% (32% absolute and 80% relative reduction). Using a 2-sided ��2 test with a significance level of 0.05 and 80% power, 27 subjects in each group and a total sample size of 54 were see more required to demonstrate the expected difference between groups. Continuous variables are presented as mean �� standard deviation and were compared using the t test for independent samples. Variables not normally distributed are presented as median and interquartile range (IQR) and compared with the Wilcoxon rank sum test. Categoric data are presented as percentages and were compared with the use of the chi-square test or the Fisher exact test as appropriate. The primary analyses were analyzed according to the intention-to-treat principle. Change over time within treatment groups was tested by means of repeated analysis of covariance. Cox regression analysis was used to estimate univariate hazard ratios and their 95% confidence intervals (CIs). Kaplan-Meier analysis was used to generate time-to-event curves for the clinical end points (rehospitalizations for congestive HF and combined end point of death and rehospitalizations for HF). All tests were 2 tailed, and a P value of